Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery

British Journal of Cancer

Volumn 102, Issue 1, 2010, Pages 73-79

  Byrne, M ^a   Reynolds, J V ^a   O'Donnell, J S ^a   Keogan, M ^a   White, B ^a   Murphy, S ^a   Maher, S G ^a   Pidgeon, G P ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Immunoinflammation; Multimodal; Oesophageal cancer; Pro coagulant

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 8A; CISPLATIN; D DIMER; ENOXAPARIN; FIBRINOGEN; FLUOROURACIL; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; VASCULOTROPIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; GASTRECTOMY; HEMOSTASIS; HUMAN; HUMAN CELL; LUNG ANGIOGRAPHY; LYMPHOCYTE ACTIVATION; MALE; MULTIMODALITY CANCER THERAPY; PARTIAL THROMBOPLASTIN TIME; PHLEBOGRAPHY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ADENOCARCINOMA; ADULT; AGED; ANTICOAGULANTS; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; CYTOKINES; ENOXAPARIN; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FACTOR VIII; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FOLLOW-UP STUDIES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; NF-KAPPA B; POSTOPERATIVE COMPLICATIONS; PULMONARY EMBOLISM; THROMBOPHILIA; TOMOGRAPHY, X-RAY COMPUTED; VENOUS THROMBOEMBOLISM;

EID: 74249109754     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605463     Document Type: Article

References (33)

1. Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, Moia M, Parazzini F, Rossi R, Sonaglia F, Valarani B, Bianchini C, Gussoni G (2006) A clinical outcome-based prospective study on venous throm-boembolism after cancer surgery: the @RISTOS project. Ann Surg 243: 89-95
2. Bailey SH, Bull DA, Harpole DH, Rentz JJ, Neumayer LA, Pappas TN, Daley J, Henderson WG, Krasnicka B, Khuri SF (2003) Outcomes after esopha-gectomy: ten year prospective cohort. Ann Thorac Surg 75: 217-222
3. Behanwala KA, Williamson RCN (2009) Cancer-associated venous thrombosis in the surgical setting. Ann Surg 249: 366-375
4. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F, ENOXACAN II Investigators (2002) Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346: 975-980 (Pubitemid 34983247)
5. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher Jr CJ (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709
6. Bone RC, Sibbald WJ, Spring CL (1992) The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 101: 1481-1483
7. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M, Sahmoud T (1997) Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N Engl J Med 337: 161-167
8. Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, Huang W, Zayaruzny M, Emery L, Anderson Jr FA, ENDORSE Investigators (2008) Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371: 387-394
9. Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349: 2241-2252
10. Esmon CT (2005) The interactions between inflammation and coagulation. Br J Haematol 131: 417-430
11. Galster H, Kolb G, Kohsytorz A, Seidlmayer C, Paal V (2000) The pre-, peri-and postsurgical activation of coagulation and the thromboembolic risk for different groups. Thromb Res 100: 381-388
12. Geerts WH, Heit JA, Clagett P, Pineo GF, Colwell CW, Anderson Jr FA, Wheeler HB (2001) Prevention of venous thromboembolism. Chest 119: 132S-1175S
13. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ (1999) Predictors of survival after deep vein thrombosis and pulmonary embolism: a population based cohort study. Arch Intern Med 159: 445-453
14. Hoffman R, Haim M, Brenner B (2001) Cancer and thrombosis revisited. Blood Rev 15: 61-67
15. Holm T, Singnomklao T, Rutqvist LE, Cedermark B (1996) Adjuvant preoperative radiotherapy in patients with rectal carcinoma. Adverse effects during long term follow-up of two randomized trials. Cancer 78: 968-976
16. Illtyd James TGI, Matheson NM (1935) Thrombophlebitis in cancer. Practitioner 134: 683-684
17. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RC (2004) Low molecular weight heparin therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 22: 1944-1948
18. Kuzel T, Esparaz B, Green D, Kies M (1990) Thrombogenicity of intravenous 5-fluorouracil alone, or in combination with cisplatin. Cancer 65: 885-889
19. Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN (2005) Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23: 2123-2129
20. McCulloch P, Ward J, Tekkis P (2003) Mortality and morbidity in gastro-esophageal cancer surgery: initial results of ASCOT multicentre prospective study. BMJ 327: 1192-1197
21. O'Donnell J, Mumorford AD, Manning RA, Laffan MA (2001) Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. Br J Haematol 115: 687-691
22. Rasmussen MS, Jorgensen LN, Wille-Jørgensen P, Nielsen JD, Horn A, Mohn AC, Sømod L, Olsen B, FAME Investigators (2006) Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomised open-label study. J Thromb Haemost 4: 2384-2390
23. Reynolds JV, Muldoon C, Hollywood D, Ravi N, Rowley S, O'Byrne K, Kennedy J, Murphy TJ (2007) Long-term outcomes following neoadju-vant chemoradiotherapy for esophageal cancer. Ann Surg 245: 707-716
24. Rickles FR, Levine MN (2001) Epidemiology of thrombosis in cancer. Acta Haematol 106: 6-12
25. Rickles R, Falanga A (2001) Molecular basis for the relationship between thrombosis and cancer. Thromb Res 102: V215-V244
26. Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ (2007) Venous thromboembolism in the outpatient setting. Arch Int Med 167: 1471-1475
27. Tetzlaff ED, Correa AM, Baker J, Ensor J, Ajani JA (2007) The impact on survival of thromboembolic phenomena occur ring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma. Cancer 109: 1989-1995
28. Tetzlaff ED, Correa AM, Komaki R, Swisher SG, Maru D, Ross WA, Ajani JA (2008) Significance of thromboembolic phenomena occurring before and during chemoradiotherapy for localised carcinoma of the esophagus and gastroesophageal junction. Dis Esophagus 21: 575-581
29. Trousseau A (1865) Phlegmasia alba dolens. In Clinique Medicale de L'hotel-Dieu de Paris, Trousseau A (ed), Vol.3 654-712. Balliere: Paris, France
30. Tsai AW, Cushman M, Rosamond W, Heckbert RS, Tracy RP, Aleksic N, Folsom AR (2002) Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboem-bolism etiology (LITE). Am J Med 113: 636-642 (Pubitemid 36015799)
31. Tufia C, Haddad D, Edward W (2006) Chemotherapy-induced thrombosis. Thromb Res 118: 555-568
32. Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J (2005) Drotrecogin alpha (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33: 2266-2277
33. Zwicker J, Furie B (2007) Cancer-associated thrombosis. Crit Rev Oncol Hematol 62(2): 126-136